The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health Corp., Cigna Group and ...

The FTC believes that the PBMs participated in unjust competition and practices, incentivizing manufacturers to increase insulin list prices. “Express Scripts intends to vigorously defend itself to ...

The FTC alleges that these practices have inflated insulin prices, restricted patient access to lower-priced alternatives, ...

The drug gatekeepers favored versions of insulin with higher upfront prices and bigger rebate payments from pharmaceutical companies, which shifted more costs onto patients, the FTC alleged.

The Federal Trade Commission on Friday filed an administrative complaint against the three largest pharmacy benefit managers and their affiliated group purchasing organizations, alleging they have ...

The FTC said a big issue is that PBMs' revenue is tied to rebates and fees — which are based on a percentage of a drug’s list price. Essentially, in the case of insulin, when the drug costed ...

in the US for operating a "perverse drug rebate system" that it claims artificially inflated the prices of insulin products. The lawsuit – which has been anticipated since the FTC published a ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

Insulin prices have skyrocketed in recent years, working a hardship on the growing number of diabetics in the US. Progressive ...

The FTC accuses major PBMs of inflating insulin prices, impacting patient costs and access to affordable medications. PBMs prioritize high-rebate drugs, contributing to high insulin prices and ...

The drug gatekeepers favored versions of insulin with higher upfront prices and bigger rebate payments from pharmaceutical companies, which shifted more costs onto patients, the FTC alleged. The PBMs ...